Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2026)

Mangoceuticals has disclosed Other Operating Expenses across 4 years of filings, most recently posting $2.1 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $2.1 million, down 32.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (up 97.7% YoY), and the FY2025 annual result was -$125624.0, down 102.35% from the prior year.
• Other Operating Expenses came in at $2.1 million for Q1 2026 at Mangoceuticals, up from -$241976.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $7.3 million in Q3 2025 to a low of -$241976.0 in Q4 2025.
• The 4-year median for Other Operating Expenses is $1.8 million (2023), against an average of $2.3 million.
• Peak annual rise in Other Operating Expenses reached 453.0% in 2025, while the deepest fall reached 126.78% in 2025.
• Mangoceuticals' Other Operating Expenses stood at $1.9 million in 2023, then slumped by 52.13% to $903710.0 in 2024, then plunged by 126.78% to -$241976.0 in 2025, then jumped by 968.35% to $2.1 million in 2026.
• The last three Other Operating Expenses figures came in at $2.1 million (Q1 2026), -$241976.0 (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.